Induced cardiomyocytes stained with cardiac markers (red = cTNT, green = Myl2, blue = DAPI)
Courtesy of Hoerstrup lab (Melanie Generali)
Full Professor and Managing Director
Institute for Regenerative Medicine (IREM), University of Zurich
Research Focus: We are working at the interface of basic science and translational research in the field of Regenerative Medicine. So far, we have established the reprogramming of mouse and human cells into iPSC using diverse reprogramming technologies (Retrovirus, Lentivirus, Sendai Virus, Episomal vectors). These cells have been differentiated into either endothelial cells, smooth muscle cells or beating cardiomyocytes. Human iPSC-derived cells have been used for tissue engineering of vascular grafts.
Currently, our team is focused on the generation of human iPSC/iPSC-derived cell without using serum or xenogenic reagents for clinical applications. Using microRNA-responsive synthetic mRNAs (RNA switches) we have started to establish - in collaboration with Center for iPS Cell Research and Application (CiRA), Kyoto University - the purification of hiPSC-derived cells, especially the specific elimination of hiPSC.
Methods: Reprogramming of human fibroblasts or peripheral mononuclear blood cells; Differentiation of hiPSC into endothelial cell, smooth muscle cells or cardiomyocytes; Purification of differentiated cells using RNA Switch technology
Keywords: Induced pluripotent stem cells (iPSCs), Cardiac diseases, Myocardial Infarction,
Topics: Tissue Engineering, Cardiac Regeneration, Clinical Translation